Published online 16 June 2009
Haematologica, Vol 94, Issue 7, 984-993 doi:10.3324/haematol.2008.002436
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slany, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slany, R. K.
Related Collections
Right arrowRelated Article

Acute Leukemia

The molecular biology of mixed lineage leukemia

Robert K. Slany

Department of Genetics, University Erlangen, Erlangen, Germany

Correspondence: Robert K. Slany, Genetics, University Erlangen, Staudtstrasse 5, 91058 Erlangen, Germany. E-mail:rslany{at}biologie.uni-erlangen.de

Mixed lineage leukemia is a very aggressive blood cancer that predominantly occurs in pediatric patients. In contrast to other types of childhood acute leukemias, mixed lineage leukemia presents with a dismal prognosis and despite the availability of advanced treatment methods cure rates have stagnated over the last years. Mixed lineage leukemia is characterized by the presence of MLL fusion proteins that are the result of chromosomal translocations affecting the MLL gene at 11q23. These events juxtapose the amino-terminus of the histone methyltransferase MLL with a variety of different fusion partners that destroy normal histone methyltransferase function of MLL and replace it by heterologous functions contributed by the fusion partner. The resulting chimeras are transcriptional regulators that take control of targets normally controlled by MLL with the clustered HOX homeobox genes as prominent examples. Recent studies suggested that MLL fusion partners activate transcription by two different mechanisms. Some of these proteins are themselves chromatin modifiers that introduce histone acetylation whereas other fusion partners can recruit histone methyltransferases. In particular, histone H3 specific methylation at lysine 79 catalyzed by DOT1L has been recognized as a hallmark of chromatin activated by MLL fusion proteins. Interestingly, several frequent MLL fusion partners seem to coordinate DOT1L activity with a protein complex that stimulates the elongation phase of transcription by phosphorylating the carboxy-terminal repeat domain of RNA polymerase II. The discovery of these novel enzymatic activities that are essentially involved in MLL fusion protein function presents potential new targets for a rational drug development.

Key words: MLL, proteins, leukemia.


Related Article

Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!
Marie C. Béné
Haematologica 2009 94: 891-893. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
B. J. Lange
T(11q23): brand necessary
Blood, September 17, 2009; 114(12): 2365 - 2366.
[Full Text] [PDF]

Home page
 haematolHome page
M. C. Bene
Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!
Haematologica, July 1, 2009; 94(7): 891 - 893.
[Full Text] [PDF]